Abstract
As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Keywords: post-transcription modification, HDAC6, structure, cancer, selective inhibitor, histone deacetylation.
Current Medicinal Chemistry
Title:Recent Development of Novel HDAC6 Isoform-selective Inhibitors
Volume: 28 Issue: 21
Author(s): Yunpeng Zhao, Tao Liang, Xuben Hou*Hao Fang*
Affiliation:
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
Keywords: post-transcription modification, HDAC6, structure, cancer, selective inhibitor, histone deacetylation.
Abstract: As an important post-transcription modification, histone deacetylation plays significant roles in chromatin remodeling and gene expression. The aberrant modification of histone deacetylation leads to various diseases. As a critical member of histone deacetylase (HDAC), HDAC6 serves as a key modulator in many physiological processes. Abnormal expression of HDAC6 gives rise to cancer, neurodegeneration and other diseases. Here, we have reviewed recent advances in physiological, protein structure and development of HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Zhao Yunpeng , Liang Tao, Hou Xuben*, Fang Hao *, Recent Development of Novel HDAC6 Isoform-selective Inhibitors, Current Medicinal Chemistry 2021; 28 (21) . https://dx.doi.org/10.2174/0929867327666201111142653
DOI https://dx.doi.org/10.2174/0929867327666201111142653 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Zoledronic Acid -a Multiplicity of Anti-Cancer Action
Current Medicinal Chemistry Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Current Pharmaceutical Design Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Relevance of Multidrug Resistance Proteins on the Clinical Efficacy of Cancer Therapy
Current Drug Delivery Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Molecular Cytogenetics
Recent Patents on DNA & Gene Sequences Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Targeting Bcl-2 in CLL
Current Medicinal Chemistry Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Role of the Hypoxic Microenvironment in the Antitumor Activity of Tyrosine Kinase Inhibitors
Current Medicinal Chemistry Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry